Status:
COMPLETED
MRI Screening for Patients With Myelodysplastic Syndrome (MDS), Who Have Received Multiple Red Blood Cell Transfusions
Lead Sponsor:
Weill Medical College of Cornell University
Collaborating Sponsors:
Novartis Pharmaceuticals
Conditions:
Myelodysplastic Syndrome (MDS)
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
A known risk of red blood cell transfusions is that it puts excess iron into the patient's body. Researchers are continually seeking the most effective method of measuring iron concentration. The purp...
Eligibility Criteria
Inclusion
- Male or Female patients will need documentation of diagnosis of Myelodysplastic Syndrome by previous bone marrow exam
- Male or female patients with MDS who have received at least 50 units of Red Blood Cell Transfusions.
- Serum ferritin \> 1,000
- Written informed consent by the patient.
Exclusion
- Contraindication to MRI, including cardiac pacemaker, brain aneurysm clip, implanted neurostimulator, insulin pump, cochlear implant, metal slivers in the eyes, intrauterine device or any other MRI incompatible metal implants or intractable claustrophobia.
Key Trial Info
Start Date :
July 31 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 29 2013
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT00749372
Start Date
July 31 2008
End Date
March 29 2013
Last Update
October 25 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Weill Medical College of Cornell University
New York, New York, United States, 10065